This document provides an overview of regulations for combination products and medical devices in India. It defines combination products as those composed of two or more medical products like drugs, devices, and/or biologics. The regulatory authorities in India that oversee drugs and medical devices are described, including the Drugs Controller General of India and Central Drugs Standard Control Organization. The document outlines some key proposed regulations like the Indian Medical Device Regulatory Act, which would classify medical devices into four risk-based categories and establish design, manufacturing, and post-market surveillance requirements. It also discusses the role of pharmacists in understanding medical device safety and being involved in their regulation.
Investigational medical product dossierSachinFartade
Investigational medical product dossier is document made to apply for clinical trial application in European Union. European Medical Agency is regulatory body for drug approval in European Union.
Investigational medical product dossierSachinFartade
Investigational medical product dossier is document made to apply for clinical trial application in European Union. European Medical Agency is regulatory body for drug approval in European Union.
This presentation is regarding the rules in hipaa that are implemented by HHS followed by information regarding PHI(protected health information) and MNS(minimum necessary standards)in hipaa ; and how hipaa regulations followed during clinical trials
CMC, post approval regulatory affairs, etcJayeshRajput7
this document covers points such as CMC, post approval regulatory affairs, regulation for combination products, and medical devices, common technical document (CTD) and electronic common technical document (eCTD) format, industry and FDA liasion, ICH guidelines of ICH Q,S,E,M, regulatory requirements of EU, MHRA, TGA and ROW countries.
This presentation is regarding the rules in hipaa that are implemented by HHS followed by information regarding PHI(protected health information) and MNS(minimum necessary standards)in hipaa ; and how hipaa regulations followed during clinical trials
CMC, post approval regulatory affairs, etcJayeshRajput7
this document covers points such as CMC, post approval regulatory affairs, regulation for combination products, and medical devices, common technical document (CTD) and electronic common technical document (eCTD) format, industry and FDA liasion, ICH guidelines of ICH Q,S,E,M, regulatory requirements of EU, MHRA, TGA and ROW countries.
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...Mohamed Fazil M
M. Pharmacy - Pharmaceutical Regulatory Affairs (MRA)
1st Semester - Regulations and Legislation for Biologics (MRA 104T)
Unit 2 - Rules, Regulations, Guidelines and Standards for Regulatory Filing of Biologicals
CDSCO Biologicals
The Therapeutic Goods Administration is the regulatory body for therapeutic goods in Australia.he TGA is responsible for conducting assessment and monitoring activities to ensure that therapeutic goods available in Australia are of an acceptable standard and that access to therapeutic advances is in a timely manner.
Fixed dose combination products – rationality, status in india, development i...Dr Sukanta sen
The development of FDCs is becoming increasingly
important from a public health perspective.
•They are being used in the treatment of a wide range of
conditions and are particularly useful in the management of
human immunodeficiency virus/acquired immunodeficiency
syndrome (HIV/AIDS), malaria and tuberculosis, which are
considered to be the foremost infectious disease threats in the world today.
IMPLANTS
MEDICAL DEVICES
REGULATIONS IN INDIA
CLASSIFICATION OF MEDICAL DEVICES{CDSCO, FDA}
IMPLANTS
CLASSIFICATION OF IMPLANTS
IMPLANTABLE MEDICAL DEVICES
RISKS RELATED TO IMPLANTS
ADVANTAGES & DISADVANTAGES
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
Honest Reviews of Tim Han LMA Course Program.pptxtimhan337
Personal development courses are widely available today, with each one promising life-changing outcomes. Tim Han’s Life Mastery Achievers (LMA) Course has drawn a lot of interest. In addition to offering my frank assessment of Success Insider’s LMA Course, this piece examines the course’s effects via a variety of Tim Han LMA course reviews and Success Insider comments.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
Acetabularia Information For Class 9 .docxvaibhavrinwa19
Acetabularia acetabulum is a single-celled green alga that in its vegetative state is morphologically differentiated into a basal rhizoid and an axially elongated stalk, which bears whorls of branching hairs. The single diploid nucleus resides in the rhizoid.
Embracing GenAI - A Strategic ImperativePeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Palestine last event orientationfvgnh .pptxRaedMohamed3
An EFL lesson about the current events in Palestine. It is intended to be for intermediate students who wish to increase their listening skills through a short lesson in power point.
2024.06.01 Introducing a competency framework for languag learning materials ...Sandy Millin
http://sandymillin.wordpress.com/iateflwebinar2024
Published classroom materials form the basis of syllabuses, drive teacher professional development, and have a potentially huge influence on learners, teachers and education systems. All teachers also create their own materials, whether a few sentences on a blackboard, a highly-structured fully-realised online course, or anything in between. Despite this, the knowledge and skills needed to create effective language learning materials are rarely part of teacher training, and are mostly learnt by trial and error.
Knowledge and skills frameworks, generally called competency frameworks, for ELT teachers, trainers and managers have existed for a few years now. However, until I created one for my MA dissertation, there wasn’t one drawing together what we need to know and do to be able to effectively produce language learning materials.
This webinar will introduce you to my framework, highlighting the key competencies I identified from my research. It will also show how anybody involved in language teaching (any language, not just English!), teacher training, managing schools or developing language learning materials can benefit from using the framework.
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
Francesca Gottschalk - How can education support child empowerment.pptxEduSkills OECD
Francesca Gottschalk from the OECD’s Centre for Educational Research and Innovation presents at the Ask an Expert Webinar: How can education support child empowerment?
Overview on Edible Vaccine: Pros & Cons with Mechanism
Combinational products & medical devices
1. REGULATION FOR COMBINATION OF PRODUCTS &
MEDICAL DEVICES
PRESENTED BY GUIDE
MR. SHUBHAM GAJANAN WAGH PROF. DR.S.D.PANDE
M.pharm (pharmaceutics)
VIDYA BHARATI COLLEGE OF PHARMACY, AMRAVATI-444602
2021-22
2. INDEX
Sr. No. Contents Page No.
1 Introduction 3
2 Types of combination products 4
3 Examples of combination products 5
4 Regulatory authorities 6
5 Medical devices 7
6 Regulation of medical devices in India 8
7 Indian Medical Device Regulatory Act (IMRDA) 9
8 I.M.R.D.A. essential principles & objectives 10
9 I.M.R.D.A. regulation 11
10 I.M.R.D.A. Classification of medical devices 12
11 The Drug and Cosmetic Act 13
12 Significance & role of pharmacist in use of medical devices 14
13 Latest development in medical device regulation 15
14 References 16
2
3. INTRODUCTION
Definition of a combination product
A combination product is a product composed of two or more different types of medical
products (i.e. a combination of a drug, device, and/or biological product with one
another). The drugs, devices, and biological products included in combination products
are referred to as “constituent parts” of the combination product.
3
4. TYPES OF COMBINATION PRODUCTS
Under 21 CFR 3.2(e), a combination product includes:
A product comprised of two or more regulated components ( i.e. drug/device, biologic/device, drug/biologic, or
drug/device/biologic)that are physically, chemically, or otherwise combined or mixed and produced as a single
entity (often referred as to “single entity” combination product)
Two or more separate products packaged together in a single package or as a unit and comprised of drug and
device products, device and biological products, or biological and drug products (often referred as to “co-
packaged” combination product)
A drug, device, or biological product packaged separately that according to its investigational plan or proposed
labeling is intended for use only with an approved, individually specified drug, device, or biological product
where both are required to achieve the intended use, indication, or effect and where upon approval of the
proposed product the labeling of the approved product would need to be changed (e.g., to reflect a change in
intended use, dosage form, strength, route of administration, or significant change in dose) (often referred as
“cross-labeled” combination product); or
Any investigational drug, device, or biological product packaged separately that according to its proposed
labeling is for use only with another individually specified investigational drug, device, or biological product
where both are required to achieve the intended use, indication, or effect (another type of cross-labeled
combination product).
4
5. EXAMPLES OF COMBINATION PRODUCTS
5
Examples of single-entity combination products (where the components are physically, chemically or
otherwise combined) (21 CFR 3.2(e)(1)):
Monoclonal antibody combined with a therapeutic drug
Device coated or impregnated with a drug or biologic
(Drug-eluting stent, pacing lead with steroid-coated tip, catheter with antimicrobial coating, condom with
spermicidal, transdermal patch)
Prefilled drug delivery systems
(Syringes, insulin injector pen, metered dose inhaler)
Examples of co-packaged combination products (the components are packaged together) (21 CFR
3.2(e)(2)):
Drug or vaccine vial packaged with a delivery device
Surgical tray with surgical instruments, drapes, and anesthetic or antimicrobial swabs
First-aid kits containing devices (bandages, gauze), and drugs (antibiotic ointments, pain relievers)
Example a of product that may be cross-labeled combination products (components are separately
provided but specifically labeled for use together) (21 CFR 3.2(e)(3) or (e)(4)):
Photosensitizing drug and activating laser/light source
6. REGULATORY AUTHORITIES
The regulatory authorities in India are as follow:
Drugs Controller General of India (DCGI). This is part of the Ministry of Health and Family Welfare.
Central Drugs Standard Control Organization(CDSCO). This is part of the Ministry of Health and Family
Welfare.
State drug licensing authorities.
Gazetted officers authorized by the state governments to enforce drug advertising regulations.
National Pharmaceutical Pricing Authority (NPPA). This is part of the Ministry of Chemicals and
Fertilizers.
Department of Pharmaceuticals (DOP). This is part of the Ministry of Chemicals and Fertilizers.
Department of Biotechnology (DBT). This is part of the Ministry of Environment and Forests.
Review Committee on Genetic Manipulation (RCGM). This is part of the Ministry of Science and
Technology.
Genetic Engineering Appraisal Committee (GEAC). This is part of the Ministry of Environment and
Forests.
National Medical Commission (NMC). The NMC regulates healthcare professionals practicing modern
(allopathic) medicine.
6
7. MEDICAL DEVICES
Definition
A medical device is an instrument, apparatus, in vitro reagent , implant or other similar or related
article , which is intended for use in the diagnosis of disease or other condition ,or in the cure ,
mitigation , treatment , or prevention of disease or intended to affect the structure or any function
of the body and which does not achieve any of its primary intended purposes through its chemical
action within or on the body.
According to Therapeutics Goods Act 1989, it is defined as any instruments, apparatus, appliances,
material or other article (weather used alone or in combination and including software necessary
for its proper application) intended to be used for human being for:
Diagnosis, prevention, monitoring, treatment or alleviation of diseases.
Investigation, replacement or modification of the anatomy or of a physiological processes.
7
8. In India medical devices are governed by Central Drugs Standard Control Organization
(CDSCO) which is regulated by Directorate General Of Health Services, Ministry Of
Health And Family Welfare, Government Of India.
CDSCO is the only government body which regulates the medical devices.
Many committees had been setup and give their opinion and recommendation, like
Mahelkar Committee – Central Drug Standard Control Organization.
All these are now being taken into to form the Indian Medical Device regulatory Act
(IMRDA).
8
REGULATION OF MEDICAL DEVICES IN INDIA
9. INDIAN MEDICAL DEVICE REGULATORY ACT (IMRDA)
Indian Medical Devices Regulatory Act come in force December 31,2009
Inputs to be sent to Dr.B.Hari Gopal , Adviser Department of Science and Technology,
New Delhi.
The composition of the Indian Medical Device regulatory Act (IMRDA) committee is
represented by:
Central Government
Eminent Jurist
Two eminent medical practitioners
Two eminent medical technologists
Secretary General Quality council
9
10. I.M.R.D.A. ESSENTIAL PRINCIPLES & OBJECTIVES
Principles
Should not compromise health and safety.
Design and manufacture of devices must conform with safety principles.
Long term safety should be ensured.
Benefits of the devices must outweigh any side effects.
Medical devices should be useful for the intended purpose.
Objectives
Provide notification of essential principles.
Provide for risk based classification of devices.
Notify standards and guidelines.
Provide mechanism of conformity.
Provide a post market surveillance system.
Provide for enforcement.
10
11. I.M.R.D.A. REGULATION
Indian Medical Devices Regulatory Act (IMRDA) will issue:
Design and manufacturing requirements
Performance evaluation
Demonstration of device standards , testing and compliance
Regulation of post marketing follow up
Regulation of recalls
Legislate and punishment for non compliance
Principle of safety
11
12. I.M.R.D.A. CLASSIFICATION OF MEDICAL DEVICES
IMRDA classifies the medical devices on the basis of risk level
Class A– Devices involving low risk levels
Class B– Devices involving low to medium risk
Class C – Devices involving moderate to high risk
Class D– Devices involving high risk.
12
13. THE DRUG AND COSMETIC ACT
The Drug and Cosmetic Act regulates :
Covers the pharmaceutical products and cosmetic.
Added medical devices as early as1992(syringes , needles , etc.)
As per the latest list of regulated medical devices, issued on the 20/04/2010, listed following devices:
•Disposable hypodermic needles
•Disposable hypodermic syringes
•Disposable perfusion sets
•In vitro diagnostic devices for HIV, HbsAg.
•Cardiac stents
•Catheters
•Intra ocular lenses
Additionally following products are regulated as ‘Drugs’ under Drugs & Cosmetics Act & Rules there under:
•Blood grouping sera
•Ligatures, sutures & staplers
•Intra uterine devices
•Condoms
13
•Drug eluting stents
•I.V. cannulae
•Bone cement
•Heart valve
•Scalp vein sets
•Orthopedic implant
•Internal prosthetic replacement
•Tubal rings
•Surgical dressings
•Umbilical cord
•Blood/blood related products
14. SIGNIFICANCE & ROLE OF PHARMACIST IN USE OF MEDICAL DEVICES
14
Significance of medical devices
The medical development in terms of drugs and devices has brought about the robust change in
the life of the people. Medical devices have extended the ability of physicians to diagnose and
treat diseases, making great contributions to health and quality of life.
Like medicines and other health technologies, they are essential for patient care at the bedside,
at the rural health clinics or at the large, specialized hospitals.
Role of pharmacist in regulation and use of medical devices
Pharmacist should:
have proper understanding of medical device safety, risk involved, the degree of invasiveness,
duration of contact, the body system affected, and local versus systemic effects.
be actively involved in the regulation of effectiveness and performance of medical device.
15. LATEST DEVELOPMENT IN MEDICAL DEVICE REGULATION
There are only14 medical devices regulated by Drug Controller General of India (DCGI).
Currently, a number of specific medical devices are regulated as drugs and fall under India’s Drugs and Cosmetics Act (DCA).
Since 2008, both the Indian Department of Science and Technology and the Ministry of Health have sought to completely
restructure the regulations for medical devices.
Department of Science and Technology : proposed creation of a Medical Devices Regulatory Authority that would operate similar to
a division within the CDSCO.
Ministry of Health: proposed revision of the DCA that would create a Central Drug Authority to function similarly to the U.S.FDA.
The CDSCO is continuing to entrench its own medical device regulation standards. In June 2009, it seemed as if the CDSCO would
begin its own form of medical device regulations.
CDSCO: released schedule M-3 which provided an official definition for medical devices, outlined a four level medical device risk
classification scheme, created a body within the CDSCO to regulate medical devices in India.
Ministry of Health and Family Welfare, Government of India, with WHO funding, initiated a country wide National
Pharmacovigilance Program.
Central Drugs Standard Control Organization (CDSCO), New Delhi, coordinates the program. The Honorable Minister of Health,
Dr. Anbumani Ramadass at New Delhi, officially launched the program on November 23, 2004.
15